jmkobers, thanks for your good wishes. Yes I do value Dew's opinion. This company has a the blackest of clouds. I don't blame anyone here (Wheeler is not in the building) for not foreseeing the McPherson debacle which is largely to blame for the recent decline, otherwise MNTA would probably still be ahead of the curve. I will continue to hold for the promise of bioequivalents that may lead the way to market, especially with partners like Mylan and CSL. I followed the legal cases closely with the help of some board members here and no one could have predicted the crazy turns that has taken. I think any investment with major appreciation potential will require risk and thinking differently than others. Ups and downs can be awful but up is better I expect setbacks and we are in one now. And yes I am waiting for the Dew view. Best wishes, bp
Market Data 
Markets 
AI
